Characterization of pulmonary function in Duchenne Muscular Dystrophy

Pediatric Pulmonology

Volumn 50, Issue 5, 2015, Pages 487-494

  Mayer, O H ^a   Finkel, R S ^b   Rummey, C ^c,d   Benton, M J ^a   Glanzman, A M ^a   Flickinger, J ^a   Lindstrom B M ^d   Meier, T ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NEMOURS CHILDREN S HOSPITAL   (United States)

^c Santhera Pharmaceuticals   (Switzerland)

^d Pharma Ltd   (Finland)

Author keywords

forced vital capacity; Muscular dystrophy; natural history; peak expiratory flow; pulmonary function test

Indexed keywords

DEFLAZACORT; PREDNISOLONE; PREDNISONE; GLUCOCORTICOID;

ADOLESCENT; ADULT; ARTICLE; CHILD; DUCHENNE MUSCULAR DYSTROPHY; EXPIRATORY RESERVE VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONOLOGIST; SPIROMETRY; STEROID THERAPY; COHORT ANALYSIS; DISEASE COURSE; FORCED EXPIRATORY VOLUME; LUNG; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; VITAL CAPACITY; WALKING; WALKING DIFFICULTY; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MOBILITY LIMITATION; MUSCULAR DYSTROPHY, DUCHENNE; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SPIROMETRY; VITAL CAPACITY; WALKING; YOUNG ADULT;

EID: 84927910080     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23172     Document Type: Article

References (28)

1. Emery AE,. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991; 1: 19-29.
2. Hoffman EP, Brown RH, Kunkel LM,. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
3. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L,. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988; 318: 1363-1368.
4. McDonald CM, Abresch RT, Carter GT, Fowler WM, Jr., Johnson ER, Sigford BJ,. Profiles of neuromuscular diseases-Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995; 74: S70-S92.
5. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS Consensus Statement. Am J Respir Crit Care Med 2004; 170: 456-465.
6. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, Part 2: Implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
7. Bersanini C, Khirani S, Ramirez A, Lofaso F, Aubertin G, Beydon N, Mayer M, Maincent K, Boule M, Fauroux B,. Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders. Eur Respir J 2012; 39: 1206-1212.
8. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM,. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001; 164: 2191-2194.
9. Hahn A, Bach JR, Delaubier A, Renardel-Irani A, Guillou C, Rideau Y,. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch of Phys Med and Rehabil 1997; 78: 1-6.
10. Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K,. Managing Duchenne muscular dystrophy-The additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Dis 2007; 17: 470-475.
11. Kurz LT, Mubarak SJ, Schultz P, Park SM, Leach J,. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. J Pediatr Orthop 1983; 3: 347-353.
12. Suárez AA, Pessolano FA, Monteiro SG, Ferreyra G, Capria ME, Mesa L, Dubrovsky A, De Vito EL,. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil 2002; 81: 506-511.
13. Tangsrud S, Petersen IL, Lødrup Carlsen KC, Carlsen KH,. Lung function in children with Duchenne's muscular dystrophy. Respir Med 2001; 95: 898-903.
14. Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, Hwang H, Beckett L, McDonald C, Gupta M,. The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy. Spine 2011; 36: E1009-E1017.
15. Park JH, Kang SW, Lee SC, Choi WA, Kim DH,. How respiratory muscle strength correlates with cough capacity in patients with respiratory muscle weakness. Yonsei Med J 2010; 51: 392.
16. Miller F, Moseley CF, Koreska J, Levison H,. Pulmonary function and scoliosis in Duchenne dystrophy. J Pediatr Orthop 1988; 8: 133-137.
17. Rideau Y, Jankowski LW, Grellet J,. Respiratory function in the muscular dystrophies. Muscle Nerve 1981; 4: 155-164.
18. Humbertclaude V, Hamroun D, Bezzou K, Bérard C, Boespflug-Tanguy O, Bommelaer C, Campana-Salort E, Cances C, Chabrol B, Commare M-C, et al. Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. Eur J Paediatr Neurol 2012; 16: 149-160.
19. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE,. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009; 80: 320-325.
20. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM,. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2006; 35: 36-42.
21. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K,. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th-13th May 2007, Naarden, the Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June-1st July 2007, Naarden, the Netherlands; Conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscle Dis 2008; 18: 894-903.
22. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, Part 1: Diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
23. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, King WM, Pandya S, Robison J, Schierbecker J, et al. Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy. Neurology 1989; 39: 475-481.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
25. Hankinson JL, Odencrantz JR, Fedan KB,. Spirometric reference values from a sample of the general U.S. Population. Am J Respir Crit Care Med 1999; 159: 179-187.
26. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA,. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
27. Biggar WD, Harris VA, Eliasoph L, Alman B,. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscle Dis 2006; 16: 249-255.
28. Joshi NB, Patel MP, Dongre AV,. Regression equation of height on ulnar length. Indian J Med Res 1964; 52: 1088-1091.